Investigational Drug Information for Onapristone
What is the drug development status for Onapristone?
Onapristone is an investigational drug.
There have been 11 clinical trials for Onapristone.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2023.
The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and Cystadenocarcinoma, Serous. The leading clinical trial sponsors are Context Therapeutics, Memorial Sloan Kettering Cancer Center, and Context Therapeutics Inc.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Onapristone
| US Patents | 1,649 |
| International Patents | 7,695 |
| US Patent Applications | 6,675 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,151 |
| Clinical Trial Progress | Phase 2 (2023-06-01) |
| Vendors | 20 |
Recent Clinical Trials for Onapristone
| Title | Sponsor | Phase |
|---|---|---|
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | Context Therapeutics Inc. | PHASE1 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | Context Therapeutics Inc. | Phase 1/Phase 2 |
| Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | Context Therapeutics | Phase 2 |
Clinical Trial Summary for Onapristone
Top disease conditions for Onapristone
Top clinical trial sponsors for Onapristone
US Patents for Onapristone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Onapristone | ⤷ Start Trial | Anti-FGFR3 antibodies and methods using same | Genentech Inc | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib | Genentech Inc | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Inhibition of hypoxia-inducible factor activity with carica papaya extracts | The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BEIGENE, LTD. (Grand Cayman, KY) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Antibody formulations | GENENTECH, INC. (South San Francisco, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Onapristone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Onapristone | Argentina | AR075939 | 2029-03-25 | ⤷ Start Trial |
| Onapristone | Argentina | AR119754 | 2029-03-25 | ⤷ Start Trial |
| Onapristone | Australia | AU2010229994 | 2029-03-25 | ⤷ Start Trial |
| Onapristone | Brazil | BRPI1006448 | 2029-03-25 | ⤷ Start Trial |
| Onapristone | Canada | CA2754163 | 2029-03-25 | ⤷ Start Trial |
| Onapristone | China | CN102378767 | 2029-03-25 | ⤷ Start Trial |
| Onapristone | China | CN104788564 | 2029-03-25 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
